Weight loss medication and Bariatric surgery Both have been found to be effective in helping people reduce excess pounds. And now, a new study is examining links to obesity-related cancer (ORC) risk.
Obesity is a known risk factor for certain types of cancer and has also been shown to affect cancer survival.
Obesity-related cancers include multiple myeloma, meningioma, and adenocarcinoma of the esophagus. stomach, colorectal, liver or bile duct, gallbladder, pancreas, uterus, ovaries, renal cell kidney, thyroid, and Postmenopausal breast canceraccording to the Centers for Disease Control and Prevention (CDC).
Semaglutide, a new study found shocking benefits for liver disease patients
Researchers at Clarit Health Services in Tel Aviv, Israel conducted an observational study on the medical records of 6,356 participants age 24 and older who are obese and diabetes who have no history of obesity-related cancers.
Between 2010 and 2018, half of participants took GLP-1 receptor agonist (GLP-1 RAS) – Injectable drugs For obesity and type 2 diabetes – at least 6 drug purchases within 12 months. The other half had obesity metabolism surgery (BMS).
Obesity is a known risk factor for certain types of cancer and has also been shown to affect cancer survival. (istock)
After adjusting for other factors, the researchers determined that ORC occurred in 5.62 cases per 1,000 person-years of those undergoing surgery and 5.89 cases per 1,000 person-years of those taking GLP-1.
Overall, this study determined that “the direct effect of GLP1-RA compared to BMS on the risk of ORC beyond its weight bearing effect is estimated to be a relative risk reduction of 41%.”
Here are the reasons why belly fat is more common with age and three ways to prevent it
The findings were published in the Journal Eclinical Medicine.
“The results show that there are additional paths Weight loss “GLP-1RA contributes to lowering the risk of obesity-related cancers,” Dr. Yael Wolff Sagy, Head of Research at Clalit Health Services, told Fox News Digital.
How does GLP-1 RAS affect cancer risk?
Niketa Patel, professor of molecular medicine at the USF Health Morsani College of Medicine in Tampa, Florida, noted that obesity is associated with chronic inflammation.
“GLP1-RA has been shown to reduce inflammation and reduce the risk of developing ORC,” she told Fox News Digital. (Patel was not involved in the research.)
“The anti-inflammatory properties of these drugs address a variety of known risk factors for cancer.”
“Conclusion: Obesity can cause certain cancers Treatment of obesity Using GLP1-RA reduces the risk of obesity-related cancers alone. ”
Dr. Britta Reierson, medical director at IncoundWell, a provider of metabolic health services, said there are several ways that GLP-1 RAS can have cancer palliative properties.
“Firstly, the anti-inflammatory properties of these drugs address a variety of known risk factors for cancer,” the doctor, who was not part of the Minnesota-based study, told Fox News Digital.
Overall, this study determined that “the direct effect of GLP1-RA compared to BMS on the risk of ORC beyond its weight bearing effect is estimated to be a relative risk reduction of 41%.” (istock)
“Secondly, regulation and improvement of metabolism from these drugs, including lower blood sugar levels and lower insulin resistance, can be reduced. Cancer risk. ”
New evidence also suggests that GLP-1 Ras may have a direct antitumor effect, Reierson noted – “through modulation of immune responses and epigenetic changes (occurring in gene expression and passing on to future generations).”
The first GLP-1 tablet for weight loss, diabetes shows success in late trials
Studies suggest that GLP-1 drugs can help reduce inflammation, including weight loss, as well as other organs in the body. heartaccording to Dr. Susan Savery, board-certified obesity medicine and primary care physician of PlushCare, a virtual health platform that provides primary care, therapy and weight management services.
“Over time, chronic inflammation can be a risk factor for the development of cancer, as it can damage cellular DNA,” San Francisco-based Savery, who was not involved in the study, told Fox News Digital.
The researchers determined that ORC occurred in 5.62 cases per 1,000 person-years of those undergoing surgery and 5.89 cases per 1,000 person-years of those taking GLP-1. (istock)
“Our adipose cells (adipocytes) produce naturally inflammatory cells, just like bariatric surgery, and GLP-1 drugs help reduce this inflammation by reducing the amount of adipose tissue through weight loss.”
Potential limitations
The study had several limitations, the researchers acknowledged.
“First of all, it’s an observational study. That means that our comparison group (people who had surgery and those who had GLP1-RA) may still have some remaining differences despite our methodological efforts,” Sagy told Fox News Digital.
Click here to get the Fox News app
“But only this type of real life Observational research It can provide the long follow-up period required to assess the risk of developing cancer.
Another limitation is that the major drugs included in this study are liraglutide (Saxenda, Viktuza), with fewer people taking exenatide (byetta) and duraglutide (trulicity).
While the GLP-1 RA is a “great tool” to support people on their weight loss journeys, Savery noted that maintaining a healthy lifestyle through nutritious diet and regular physical activity is “cancer prevention and improving overall health.” (istock)
“It is important to assess the comparative efficacy of new GLP1-RA drugs, which are expected to have greater effects,” says Sagy.
“The outcome direction is promising, but we need to wait and see if and how clinical guidelines will take that into consideration.”
Click here to sign up for our health newsletter
Reierson agreed to that a lot. More research GLP-1 is required before RAS is considered a cancer prevention option.
“Big, randomized controlled trials are needed to confirm the observed effects and better understand the underlying mechanisms,” she said.
“It is also important to investigate the effects of GLP-1 RAS on various types of cancer and to assess the long-term safety and potential side effects of using GLP-1 RAS as a cancer therapy.” (American Cancer Association/Getty Images)
“It is also important to investigate the effects of GLP-1 RAS on various types of cancer and to assess the long-term safety and potential side effects of using GLP-1 RAS as a cancer therapy.”
Savery agrees that it is likely too early to predict FDA approval for cancer treatments, but said, “Weight loss plays an important role in cancer prevention, and GLP-1 appears to provide additional benefits through reduced inflammation.”
For health articles, please visit www.foxnews.com/health
The GLP-1 RA is a “great tool” to help people on their weight loss journeys, but Savery is A healthy lifestyle Through nutritious diet and regular physical activity, it is a “basic of cancer prevention and improved overall health.”
